Alexion wins approval for rare disease drug, aims to switch patients from blockbuster Soliris
Alexion Pharmaceuticals secured approval for a new drug that will ultimately replace the biotech’s current blockbuster product, Soliris.
Alexion Pharmaceuticals secured approval Friday from the Food and Drug Administration for a new drug called Ultomiris that will be used to treat an ultra-rare blood disease and ultimately replace the biotech’s current blockbuster, Soliris.
The initial Ultomiris approval granted by FDA is to treat patients with paroxysmal nocturnal hemoglobinuria, or
